Table 3.
IMC outcomes stratified by the number of SIT doses
| Covariate | 1–2 doses N = 54 | ≥ 3 doses N = 30 | P |
|---|---|---|---|
| Multiple hospitalization, No. (%) | 25 (46) | 10 (33) | 0.356 |
| Failed steroid tapering after SIT, No. (%)a | 13 (27) | 15 (52) | 0.030 |
| Infliximab, No. (%) | 49 (91) | 3 (10) | < 0.001 |
| Endoscopic features, No. (%) | 0.388 | ||
| Ulcer | 17 (49) | 13 (45) | |
| Non-ulcerative inflammation | 14 (40) | 9 (31) | |
| Normal | 4 (11) | 7 (24) | |
| Endoscopic remission, No. (%)b | 9 (64) | 14 (67) | 1.000 |
| Histologic remission, No. (%)b | 7 (44) | 17 (71) | 0.087 |
| Infectious adverse events, No. (%) | 16 (30) | 9 (30) | 1.000 |
| Recurrent IMC, No. (%) | 15 (28) | 1 (3) | 0.008 |
| Calprotectin after SIT, mean (SD) | 312 (325) | 118 (138) | 0.011 |
| Mean calprotectin difference before and after SIT, (SD) | 234 (204) | 222 (165) | 0.882 |
aAvailable for the 79 patients who received steroids
bAvailable for 40 patients
Abbreviation: SIT, selective immunosuppressive therapy